Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer
暂无分享,去创建一个
M. Reeves | Matthew J. Selleck | M. Senthil | J. Morgan | S. Lum | K. Bahjri | B. Jabo | Majed M Ramadan | C. Garberoglio | Mayada Aljehani | Laurel Guthrie
[1] E. Van Cutsem,et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.
[2] S. Barni,et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[3] O. Clark,et al. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis , 2016, BMC Cancer.
[4] P. Gibbs,et al. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. , 2016, Clinical colorectal cancer.
[5] M. Lai,et al. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study , 2016, BMC Cancer.
[6] J. Meyerhardt,et al. Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). , 2016 .
[7] H. Lenz,et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. , 2015, Journal of the National Cancer Institute.
[8] C. Underhill,et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. , 2015, European journal of cancer.
[9] M. Delorenzi,et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Stauch,et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial , 2014, Journal of Cancer Research and Clinical Oncology.
[11] Sabine Tejpar,et al. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. , 2013, Clinical colorectal cancer.
[12] T. Hansen,et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] R. Greil,et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] D. Xie,et al. No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis , 2012, PloS one.
[15] T. VanderWeele,et al. Recommendations for presenting analyses of effect modification and interaction. , 2012, International journal of epidemiology.
[16] Maureen A. Smith,et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Gibbs,et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.
[18] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Stauch,et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] C. Compton,et al. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.
[21] H. Lippert,et al. Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival , 2010, Diseases of the colon and rectum.
[22] Zoran Bursac,et al. Purposeful selection of variables in logistic regression , 2008, Source Code for Biology and Medicine.
[23] Y. Collan,et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. , 2008, Anticancer research.
[24] N. Ahuja,et al. Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers? , 2008, Annals of Surgical Oncology.
[25] F. Brunicardi,et al. Schwartz's Principles of Surgery , 2004 .
[26] B. Iacopetta. Are there two sides to colorectal cancer? , 2002, International journal of cancer.
[27] W. Wright,et al. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups , 2001, Cancer Causes & Control.
[28] J. Bufill,et al. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. , 1990, Annals of internal medicine.
[29] C. Muir,et al. International Classification of Diseases for Oncology , 1990 .
[30] R. Beart. The Colon, Rectum and Anus , 1933, Cancer.
[31] S. Gruber,et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.